Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir (SD-CRF)
Efficacy and Safety of Sofosbuvir and Daclatasvir in Treating Patients With Hepatitis C and Renal Failure.
Sponsor: Ahvaz Jundishapur University of Medical Sciences
This PHASE4 trial investigates Chronic Renal Failure and Hepatitis C, Chronic and is currently completed. Ahvaz Jundishapur University of Medical Sciences leads this study, which shows 11 recorded versions since 2017 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 6 earlier versions
-
Mar 2019 — Oct 2019 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jan 2019 — Mar 2019 [monthly]
Active Not Recruiting PHASE4
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE4
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
Status: Recruiting → Active Not Recruiting
-
Jun 2017 — Mar 2018 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Mar 2017 — Jun 2017 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ahvaz Jundishapur University of Medical Sciences
- Hamadan University of Medical Science
- Shiraz University of Medical Sciences
- Tehran University of Medical Sciences
For direct contact, visit the study record on ClinicalTrials.gov .